Surmodics, Inc. (SRDX) recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the proposed acquisition of Surmodics by funds affiliated with GTCR LLC (“GTCR”).The FTC has moved to block the proposed acquisition of Surmodics by private equity firm GTCR. The deal, signed in May 2024 and valued at approximately $627 million, or$43.00 per share in cash, represented a substantial premium on the company’s market value. However, the FTC cited anti-competitive concerns, spe ...